Food Allergy

This month in review spotlights 6 top allergy stories, from falling peanut allergy rates to intranasal steroid cream easing post-surgical rhinosinusitis.

Gabryszewski said new data confirm early introduction guidelines are working, showing real-world declines in peanut allergy.

New data show peanut allergy rates have dropped sharply since early introduction guidelines, reducing 27% and 43% after the 2015 and 2017 guidelines, respectively.

Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.

Research links Treg activity, B-cell suppression, and gastrointestinal immune regulation to the success and failure of peanut oral immunotherapy.

A discrete choice experiment revealed food allergy treatment preferences among adolescents, with efficacy ranking as the most important attribute.

In a study of children with food allergy and atopic dermatitis, longer dupilumab use was associated with significantly lower food-specific IgE levels.

New research has indicated increased food tolerance thresholds and desensitization from omalizumab and other biologics in comparison to placebo with no serious adverse effects.

These data compare the characteristics and trends of anaphylaxis caused by goat and sheep’s milk allergies with those of cow’s milk and peanut allergy.

Although the evidence is not certain, this network meta-analysis indicates that certain alternate formulas may provide needed nutrients without triggering the allergy.

New findings reveal significant systemic symptoms in pediatric patients with PR-10-related pollen food allergy syndrome, highlighting the need for better management strategies.

New research reveals that maternal avocado consumption during pregnancy significantly reduces the risk of infant food allergies.

Skin prick test showed limited symptom correlation and shrimp-specific IgE demonstrated greater diagnostic value than tropomyosin-specific IgE.

AI enhances prediction, diagnosis, and treatment of allergic diseases including asthma, atopic dermatitis, and food allergies, offering personalized, efficient care.

The phase 3 REALISE study found EPIT with VP250 had a strong safety profile, with severe adverse events dropping from 9.7% in year 1 to 0.3% in year 3.

In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.

In this video, part 4 of a 5-part series, panelists discuss gaps in clinician education regarding food allergies and anaphylaxis.

In this video, part 2 of a 5-part series, panelists discuss unmet needs in pediatric food allergy research and clinical care.

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

This February 2025 month in review covers key updates in allergy, including advancements in immunotherapy and new insights on food allergy desensitization.

A phase 2 trial found that 100% of children on peanut oral immunotherapy tolerated 9043 mg of peanuts, vs 10% in the avoidant group.

Although omalizumab demonstrated superiority over oral immunotherapy, the treatments had comparable effectiveness when excluding dropouts from the analysis, Wood said at AAAAI.

HCPLive spoke with Cohen about how patients with a peanut allergy responded to oral immunotherapy with autoclaved peanuts.